5 Conclusion
We have successfully used a model based approach to explore the relative
impact of alternative dosing regimens proposed in different dosing
protocols for HCQ.
It was clear from our results that there is an unmet need for adequate
characterization of target PK exposures in COVID-19 patients to inform
the dosing optimization. Literature data and clinical data from a
Belgian hospital confirm the variability in clinical responses when same
fixed doses are given to all patients. Some confounding factors were
identified that should be taken into account for dose recommendation.
For 80% of patients in Saint Pierre cohort, doses higher than 600-800mg
daily on day 1 followed by 400-600mg daily on following days might not
be needed for positive outcome. Very limited ADRs have been reported so
far for this dosing regimen, moreover they were most often confounded by
co-medications, comorbidities or underlying disease effects.
Acknowledgements